What explains the sharp rally in Natco Pharma?
Answer
Answer
Answer
Natco Pharma surged 20% to Rs.1,189 after it got approval from the USFDA for the generic version of Celgene's multiple myeloma drug in the US. This capsule is administered to adults with multiple myeloma and myelodysplastic syndromes. Natco also started Phase-III clinical trials to test efficacy and safety of Molnupiravir Capsules aimed at mild COVID-19 patients